EdiGene

博雅辑因 | 辑生命之密码 解世间之顽疾

Beijing, China · Founded 2016 · $129.0M raised

Headquarters
Beijing
Founded
2016
Business Model
B2B
Total Funding
$129.0M
Last Round
$62.0M Series BApr 2021
Rounds
2

About

EdiGene develops genome-editing technologies and translates them into cell and gene therapies for genetic diseases and cancer. Its research and development platforms include LEAPER for in vivo RNA base editing, MAGIC for immune-compatible cell therapies, targeted-therapy high-throughput genomic-editing screening, and bioinformatics capabilities. The company develops ex vivo, in vivo, and targeted therapeutic programs and states that it is focused on converting frontier gene-editing science into innovative therapies.

Summary

EdiGene is a Biotech company based in Beijing, China, founded in 2016. It has raised $129.0M in total across 2 rounds, most recently a $62.0M Series B round in Apr 2021. Investors include 3H Health, Loyal Valley Capital and IDG Capital.

Tech & App Stack

1 technology or app tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries B PlusApr 2021
$62.0M

Sign up to see all 2 events

Funding: Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

EdiGene on Indexed.vc
<a href="https://indexed.vc/companies/edigene"><img src="https://indexed.vc/api/badge/company/edigene" alt="EdiGene on Indexed.vc" width="260" height="76" /></a>